论文部分内容阅读
关于氨基甙类抗生素耳毒性的评价,很难在人体上进行实验性观察,主要依据动物试验。一般认为该类抗生素的耳毒性强度是按下列顺序排列的:GM(gentamicin,庆大霉素)>TOB(tobramycin,托普霉素)>DKB(dibekacin,双脱氧卡那霉素)>KM(卡那霉素)>AMK(amikacin,丁胺卡那霉素)。GM毒性最强,AMK最弱。但在临床上各药物的耳毒性反应发生率与上述顺序并非一致,据某些文献报道,AMK的耳毒反应发生率比GM、TOB为高。现时在临床上各种药物的使用剂量有增大趋势,因此对耳毒性与用
On the evaluation of aminoglycoside ototoxicity, it is difficult to conduct experimental observations in humans, mainly based on animal experiments. The ototoxicity of such antibiotics is generally considered to be in the following order: GM (gentamicin)> TOB (tobramycin)> DKB (dibekacin)> KM Kanamycin)> AMK (amikacin, amikacin). GM is most toxic and AMK is the weakest. However, in clinical practice, the incidence of ototoxic reactions of each drug is not consistent with the above sequence. According to some reports, the incidence of ototoxicity in AMK is higher than that of GM and TOB. Currently in clinical use of various drugs have an increasing dose, therefore, ototoxicity and use